Please assess the completion status of the following clinical trial:

Trial Title: DESyne X2 Post Market Follow-up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient must be ≥ 18 years of age.~2. The patient must have stable angina pectoris as defined by the Canadian Cardiovascular Society Classification, documented silent ischemia, acute coronary syndrome, or a positive functional study requiring treatment~3. The patient is considered a candidate for coronary stent implantation and has a planned intervention of up to two lesions located in separate major epicardial territories. Each lesion/vessel must meet the following criteria:~   1. De novo lesion~  2. The target lesion reference site must be visually estimated to be ≥ 2.5 mm and ≤ 4.0 mm in diameter~  3. The target vessel must be a major coronary artery or major branch with a visually estimated stenosis of ≥ 50% and \< 100%.~  4. The visually estimated target lesion length must be ≤ 34 mm~  5. ≥ TIMI 1 coronary flow~Exclusion Criteria:~1. The patient has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel or ticagrelor, heparin/bivalirudin, mTOR inhibitor class drugs, cobalt chromium alloy, methacrylate or polylactide polymer, or sensitivity to contrast which cannot be adequately premedicated~2. Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing~3. Previous placement of a stent within 10 mm distal to the target lesion~4. Previous placement of a stent proximal to the target lesion~5. Total occlusion or \< TIMI 1 coronary flow in the target vessel~6. The proximal target vessel or target lesion is severely calcified by visual assessment~7. Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the left anterior descending or left circumflex~8. Lesion involvement of a significant side branch (branch diameter \> 2 mm) that would be covered by stenting~9. High probability that treatment other than PTCA or stenting will be required for treatment of the same lesion~10. The target lesion, or the target vessel proximal to the target lesion, contains thrombus~11. The patient has suffered a myocardial infarction within the past 72 hours and the CK or CK-MB has not returned to normal at the time of the index procedure~12. The patient is a recipient of a heart transplant~13. The patient has extensive peripheral vascular disease that precludes safe sheath insertion or extreme anti-coagulation~14. The patient is currently participating in another investigational device or drug study that has not completed the primary follow-up phase~15. Patients who are unable or unwilling to cooperate with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DESyne X2 Novolimus Eluting Coronary Stent System (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues